Yasuhito Nagai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasuhito Nagai has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Eiji Kirino
Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
3 shared publications Koichi Miyakawa
Department of Psychiatry Juntendo University Graduate School of Medicine Tokyo Japan
3 shared publicationsNarihiro Orimo
3 shared publicationsNobuto Shibata
Department of Psychiatry, Juntendo University School of Medicine; Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan [ protected]
3 shared publications- Masanobu Ito
Department of Psychiatry and Behavioral Science Juntendo University Graduate School of Medicine Tokyo Japan
2 shared publications Shuntaro Natsume
2 shared publications
Latest Publications
- Open Access
- 10 January 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 5 (1)
Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis
Background: Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine‐induced acute parkinsonism. Case Presentation: The patient was a 60‐year‐old male who suffered from depression and alcohol use disorder. When he was 50 years old, he was diagnosed with Wernicke's encephalopathy, central pontine myelinolysis‐induced parkinsonism, and dyskinesia. After remission, dyskinesia persisted and was diagnosed as tardive dyskinesia. The patient was treated with tetrabenazine and valbenazine at different times, and only valbenazine treatment induced acute parkinsonism. Conclusion: Valbenazine can cause acute parkinsonism, even in patients who have previously tolerated tetrabenazine, and especially in those with underlying basal ganglia lesions.
- 10 January 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 5 (1)
Open AccessValbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis
Background: Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine‐induced acute parkinsonism. Case Presentation: The patient was a 60‐year‐old male who suffered from depression and alcohol use disorder. When he was 50 years old, he was diagnosed with Wernicke's encephalopathy, central pontine myelinolysis‐induced parkinsonism, and dyskinesia. After remission, dyskinesia persisted and was diagnosed as tardive dyskinesia. The patient was treated with tetrabenazine and valbenazine at different times, and only valbenazine treatment induced acute parkinsonism. Conclusion: Valbenazine can cause acute parkinsonism, even in patients who have previously tolerated tetrabenazine, and especially in those with underlying basal ganglia lesions.
- Open Access
- 28 July 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 23 (4) , 728-732
Aripiprazole Has Potential Efficacy for Antidepressant-induced Restless Legs Syndrome: A Case Series
Yasuhito Nagai, Koichi Miyakawa. Clin Psychopharmacol Neurosci 2025;23:728-32. https://doi.org/10.9758/cpn.25.1316
- 28 July 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 23 (4) , 728-732
Open AccessAripiprazole Has Potential Efficacy for Antidepressant-induced Restless Legs Syndrome: A Case Series
Yasuhito Nagai, Koichi Miyakawa. Clin Psychopharmacol Neurosci 2025;23:728-32. https://doi.org/10.9758/cpn.25.1316
- Open Access
- 19 June 2025
- Published by Elsevier in NeuroImage
- Vol. 317, 121342
Gray matter microstructure alterations with excess extra-cellular free water contribute to cognitive dysfunction in bipolar disorder: A comparative analysis with white matter pathology
- 19 June 2025
- Published by Elsevier in NeuroImage
- Vol. 317, 121342
Open AccessGray matter microstructure alterations with excess extra-cellular free water contribute to cognitive dysfunction in bipolar disorder: A comparative analysis with white matter pathology
- Open Access
- 4 October 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 3 (4) , e70011
Concomitant use of dextromethorphan and alcohol‐induced dissociation in a patient with alcohol dependence
Background: Dextromethorphan (DXM) is an over‐the‐counter drug that is commonly abused by teenagers. Its main pharmacological property is a low‐affinity N‐methyl‐d‐aspartate (NMDA) receptor antagonist.Case Presentation: We report acute psychotic dissociation induced by DXM and alcohol in a patient with alcohol dependence, which made it difficult to distinguish alcohol withdrawal symptoms with limited information. The psychotic symptoms were ameliorated by haloperidol; however, in cases of DXM abuse, haloperidol treatment should be avoided.Conclusion: In the consultation of patients with addiction, the possibility of various addictive drugs must be kept in mind. The concomitant use of DXM and alcohol causes easy dissociation and high‐dose usage of DXM and alcohol withdrawal symptoms are difficult to distinguish.
- 4 October 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 3 (4) , e70011
Open AccessConcomitant use of dextromethorphan and alcohol‐induced dissociation in a patient with alcohol dependence
Background: Dextromethorphan (DXM) is an over‐the‐counter drug that is commonly abused by teenagers. Its main pharmacological property is a low‐affinity N‐methyl‐d‐aspartate (NMDA) receptor antagonist.Case Presentation: We report acute psychotic dissociation induced by DXM and alcohol in a patient with alcohol dependence, which made it difficult to distinguish alcohol withdrawal symptoms with limited information. The psychotic symptoms were ameliorated by haloperidol; however, in cases of DXM abuse, haloperidol treatment should be avoided.Conclusion: In the consultation of patients with addiction, the possibility of various addictive drugs must be kept in mind. The concomitant use of DXM and alcohol causes easy dissociation and high‐dose usage of DXM and alcohol withdrawal symptoms are difficult to distinguish.
- Open Access
- 8 March 2024
- Published by Elsevier in Psychiatry Research Case Reports
- Vol. 3 (1)
Case series: Older age bipolar disorder with dementia
- 8 March 2024
- Published by Elsevier in Psychiatry Research Case Reports
- Vol. 3 (1)
Open AccessCase series: Older age bipolar disorder with dementia
- Open Access
- 5 January 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (1) , e36217
Factors associated with self-perceived treatment-resistance in bipolar disorder
Patients with bipolar disorder often report self-perceived treatment resistance. However, it is not known to what extent it is due to actual treatment resistance. The Juntendo University provides “Bipolar Disorder Treatment Rebuilding Program,” in which patients with self-reported treatment resistant bipolar disorder are hospitalized for 2 weeks and undergo detailed examinations. In this study, we report our experience with the initial 43 patients hospitalized during the one and half years after the launch of the program. Among the patients who underwent full assessment, only one was regarded as having genuine treatment-resistant bipolar disorder without comorbidity. In other cases, ten were not diagnosed with bipolar disorder, 3 had organic brain diseases, 12 had comorbid mental disorders and its symptoms were regarded as treatment-resistant bipolar symptoms by the patients, and 18 did not receive adequate treatment because attendant physicians did not adhere to the treatment guidelines or patients did not adhere to the treatment because of lack of insight. The number of participants was not large, and selection bias hampered the generalization of the findings. Insight and adherence were assessed without the use of validated tools. We could not verify recovery after adequate treatment because of the limited hospitalization period. The findings suggest that most patients with self-perceived treatment-resistant bipolar disorder may not have genuine treatment-resistant bipolar disorder. These results shed light on the difficulties of public education of bipolar disorder and importance of providing appropriate services for diagnosis and treatment of bipolar disorder in the community.
- 5 January 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (1) , e36217
Open AccessFactors associated with self-perceived treatment-resistance in bipolar disorder
Patients with bipolar disorder often report self-perceived treatment resistance. However, it is not known to what extent it is due to actual treatment resistance. The Juntendo University provides “Bipolar Disorder Treatment Rebuilding Program,” in which patients with self-reported treatment resistant bipolar disorder are hospitalized for 2 weeks and undergo detailed examinations. In this study, we report our experience with the initial 43 patients hospitalized during the one and half years after the launch of the program. Among the patients who underwent full assessment, only one was regarded as having genuine treatment-resistant bipolar disorder without comorbidity. In other cases, ten were not diagnosed with bipolar disorder, 3 had organic brain diseases, 12 had comorbid mental disorders and its symptoms were regarded as treatment-resistant bipolar symptoms by the patients, and 18 did not receive adequate treatment because attendant physicians did not adhere to the treatment guidelines or patients did not adhere to the treatment because of lack of insight. The number of participants was not large, and selection bias hampered the generalization of the findings. Insight and adherence were assessed without the use of validated tools. We could not verify recovery after adequate treatment because of the limited hospitalization period. The findings suggest that most patients with self-perceived treatment-resistant bipolar disorder may not have genuine treatment-resistant bipolar disorder. These results shed light on the difficulties of public education of bipolar disorder and importance of providing appropriate services for diagnosis and treatment of bipolar disorder in the community.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 34 (13) , 129-145
Functional connectivity in autism spectrum disorder evaluated using rs-fMRI and DKI
We evaluated functional connectivity (FC) in patients with adult autism spectrum disorder (ASD) using resting-state functional MRI (rs-fMRI) and diffusion kurtosis imaging (DKI). We acquired rs-fMRI data from 33 individuals with ASD and 33 healthy controls (HC) and DKI data from 18 individuals with ASD and 17 HC. ASD showed attenuated FC between the right frontal pole (FP) and the bilateral temporal fusiform cortex (TFusC) and enhanced FC between the right thalamus and the bilateral inferior division of lateral occipital cortex, and between the cerebellar vermis and the right occipital fusiform gyrus (OFusG) and the right lingual gyrus, compared with HC. ASD demonstrated increased axial kurtosis (AK) and mean kurtosis (MK) in white matter (WM) tracts, including the right anterior corona radiata (ACR), forceps minor (FM), and right superior longitudinal fasciculus (SLF). In ASD, there was also a significant negative correlation between MK and FC between the cerebellar vermis and the right OFusG in the corpus callosum, FM, right SLF and right ACR. Increased DKI metrics might represent neuroinflammation, increased complexity, or disrupted WM tissue integrity that alters long-distance connectivity. Nonetheless, protective or compensating adaptations of inflammation might lead to more abundant glial cells and cytokine activation effectively alleviating the degeneration of neurons, resulting in increased complexity. FC abnormality in ASD observed in rs-fMRI may be attributed to microstructural alterations of the commissural and long-range association tracts in WM as indicated by DKI.
- 27 November 2023
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 34 (13) , 129-145
Open AccessFunctional connectivity in autism spectrum disorder evaluated using rs-fMRI and DKI
We evaluated functional connectivity (FC) in patients with adult autism spectrum disorder (ASD) using resting-state functional MRI (rs-fMRI) and diffusion kurtosis imaging (DKI). We acquired rs-fMRI data from 33 individuals with ASD and 33 healthy controls (HC) and DKI data from 18 individuals with ASD and 17 HC. ASD showed attenuated FC between the right frontal pole (FP) and the bilateral temporal fusiform cortex (TFusC) and enhanced FC between the right thalamus and the bilateral inferior division of lateral occipital cortex, and between the cerebellar vermis and the right occipital fusiform gyrus (OFusG) and the right lingual gyrus, compared with HC. ASD demonstrated increased axial kurtosis (AK) and mean kurtosis (MK) in white matter (WM) tracts, including the right anterior corona radiata (ACR), forceps minor (FM), and right superior longitudinal fasciculus (SLF). In ASD, there was also a significant negative correlation between MK and FC between the cerebellar vermis and the right OFusG in the corpus callosum, FM, right SLF and right ACR. Increased DKI metrics might represent neuroinflammation, increased complexity, or disrupted WM tissue integrity that alters long-distance connectivity. Nonetheless, protective or compensating adaptations of inflammation might lead to more abundant glial cells and cytokine activation effectively alleviating the degeneration of neurons, resulting in increased complexity. FC abnormality in ASD observed in rs-fMRI may be attributed to microstructural alterations of the commissural and long-range association tracts in WM as indicated by DKI.
- Open Access
- 30 June 2023
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 2 (3) , e117
Late‐onset bipolar disorder with dementia: A review of Japanese case reports
- 30 June 2023
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 2 (3) , e117
Open AccessLate‐onset bipolar disorder with dementia: A review of Japanese case reports
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (1) , 78-79
Successful Treatment of Inappropriate Sexual Behavior and Disinhibition in Dementia With Paroxetine
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (1) , 78-79
Successful Treatment of Inappropriate Sexual Behavior and Disinhibition in Dementia With Paroxetine
- Open Access
- 28 July 2022
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 1 (3)
Identification of 22q11.2 deletion in a patient with schizophrenia and clinically diagnosed Rubinstein–Taybi syndrome
Background: Rubinstein–Taybi syndrome (RTS) is a rare autosomal‐dominant disease. Almost all cases are sporadic and attributed to de novo variant. Psychotic symptoms in RTS are rare and have been reported in only a few published cases. On the other hand, 22q11.2 deletion syndrome is the most common chromosomal microdeletion in humans. The 22q11.2 deletion is well recognized as a risk factor for schizophrenia. Here, we present a schizophrenic psychosis case clinically diagnosed as RTS but resolved as carrying 22q11.2 deletion by genomic analysis.Case presentation: A 38‐year‐old Japanese male was admitted to our hospital due to psychotic symptoms. He had been diagnosed with RTS based on physical characteristics at the age of 9 months. On admission, we performed whole exome sequencing. He had no pathogenic variant in CREBBP or EP300. We detected 2.5 Mb deletion on 22q11.2 and one rare loss‐of‐function variant in a loss‐of‐function‐constrained gene (MTSS1) and three rare missense variants in missense‐constrained genes (CELSR3, HERC1, and TLN1). Psychotic symptoms were ameliorated by the treatment of risperidone.Conclusion: The psychiatric manifestation and genomic analysis may be a clue to detecting 22q11.2 deletion syndrome in undiagnosed patients. The reason for similarity in physical characteristics in 22q11.2 deletion syndrome and RTS remains unresolved. The 22q11.2 deletion and HERC1 contribute to the patient's phenotype.
- 28 July 2022
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 1 (3)
Open AccessIdentification of 22q11.2 deletion in a patient with schizophrenia and clinically diagnosed Rubinstein–Taybi syndrome
Background: Rubinstein–Taybi syndrome (RTS) is a rare autosomal‐dominant disease. Almost all cases are sporadic and attributed to de novo variant. Psychotic symptoms in RTS are rare and have been reported in only a few published cases. On the other hand, 22q11.2 deletion syndrome is the most common chromosomal microdeletion in humans. The 22q11.2 deletion is well recognized as a risk factor for schizophrenia. Here, we present a schizophrenic psychosis case clinically diagnosed as RTS but resolved as carrying 22q11.2 deletion by genomic analysis.Case presentation: A 38‐year‐old Japanese male was admitted to our hospital due to psychotic symptoms. He had been diagnosed with RTS based on physical characteristics at the age of 9 months. On admission, we performed whole exome sequencing. He had no pathogenic variant in CREBBP or EP300. We detected 2.5 Mb deletion on 22q11.2 and one rare loss‐of‐function variant in a loss‐of‐function‐constrained gene (MTSS1) and three rare missense variants in missense‐constrained genes (CELSR3, HERC1, and TLN1). Psychotic symptoms were ameliorated by the treatment of risperidone.Conclusion: The psychiatric manifestation and genomic analysis may be a clue to detecting 22q11.2 deletion syndrome in undiagnosed patients. The reason for similarity in physical characteristics in 22q11.2 deletion syndrome and RTS remains unresolved. The 22q11.2 deletion and HERC1 contribute to the patient's phenotype.